22/02/2025

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

22/02/2025

Feb 22, 2025, 13:28 | Science
Elvina Almuradova: Immunotherapy for HPV-Associated Cancers
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared an article…
Feb 22, 2025, 13:10 | Opinion
Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding
Pediatric cancer research has long been a national priority, and Senator Edward Markey, along with…
Feb 22, 2025, 13:10 | Science
Why immunotherapy has struggled in EGFR+ lung cancer - EGFR Positive Lung Cancer UK
EGFR Positive Lung Cancer UK shared an article by Maise Al Bakir, et al. on…
Feb 22, 2025, 13:04 | Blog
Debate session on the management of stage III NSCLC in the IO era - ESTRO
ESTRO shared a post on X:  "Join us for the debate session on the management…
Feb 22, 2025, 11:40 | Celebrities
Remembering Saxophonist James Casey: His Battle with Colon Cancer and Advocacy
James Casey, the celebrated saxophonist best known for his electrifying performances with the Trey Anastasio…
Feb 22, 2025, 11:36 | Career
Joseph H. Antin Received ASTCT Lifetime Achievement Award at 2025 Tandem Meetings
Dana-Farber Cancer Institute announced that Joseph H. Antin, MD, had been honored with the ASTCT…
Feb 22, 2025, 11:28 | Science
Myeloma Paper of the Day, February 22nd, suggested by Robert Orlowski
Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson…
Feb 22, 2025, 11:22 | Blog
Yan Leyfman: Great experience speaking at the NSHSS Pre-Medicine Workshop
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn by…
Feb 22, 2025, 11:15 | Insight
Henrik Ullum: The urgent need to protect WHO is also an opportunity
Henrik Ullum, Chief Executive Officer of Statens Serum Institute, shared a post on LinkedIn about…
Feb 22, 2025, 11:02 | Oncolibrary
New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Zenocutuzumab, a bispecific HER2/HER3 antibody, has emerged as a promising treatment for patients with NRG1…
All: 49 Posts: 11 - 20
Special Coverage